Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Mortality and Paclitaxel Devices, Data Are Aligning

5 years ago, several prospective randomized studies confirmed paclitaxel coated balloons were safe and effective in femoropopliteal territory. However, a recently published meta-analysis of heterogeneous studies including both paclitaxel coated balloons and drug eluting stents has linked these devices to mortality. In addition, higher doses were associated to higher mortality, both at 2 and 5 years.

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

This new meta-analysis soon to be published in J Am Coll Cardiol seeks to determine whether this association really exists in 1980 patients followed up at 5 years.

Data from 4 randomized independently adjudicated prospective studies, 2 including 1837 patients receiving paclitaxel coated balloons and 2 including 143 control patients receiving uncoated conventional balloons, were included. A thorough analysis of patient baseline characteristics was carried out and followed at long term to prove whether or not the use of paclitaxel had a positive correlation with mortality. Survival rate and dose tercile were taken into account.


Read also: Post TAVR New Onset Left Bundle Branch Block at Long Term: Worth Our Attention?


All efforts were coordinated to shed light on this link that both interventionists and patients are so concerned about, seeing as the latter have already been treated with these devices.

There was no significant association between all-cause mortality and paclitaxel coated balloons at 5-year follow-up (9.3% vs. 11.2%; p=0.399). No deaths were independently adjudicated to these devices.

When dividing patients according to dose tercile, there were no differences between patients receiving the higher dose vs. patients with the lower dose of paclitaxel (p=0.7).

Conclusion

This new meta-analysis shows paclitaxel coated balloons are safe and are not liked to increased mortality, even in patients with higher doses.

Original Title: Mortality Not Correlated With Paclitaxel Exposure An Independent Patient-Level Meta-Analysis.

Reference: Peter A. Schneider et al. J Am Coll Cardiol 2019; Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

C-TRACT: Endovascular therapy in post-thrombotic syndrome due to iliac obstruction

Post-thrombotic syndrome (PTS) is one of the most limiting sequelae following proximal deep vein thrombosis (DVT). It clinically manifests as chronic pain, edema, skin...

Coil embolization of segmental arteries as a spinal cord protection strategy prior to complex endovascular repair of thoracoabdominal aorta

Spinal cord ischemia remains one of the most devastating complications in the repair of thoracoabdominal aneurysms, with incidences of up to 20–30% in extensive...

Mechanical thrombectomy versus anticoagulation in intermediate-risk pulmonary embolism: systematic review and meta-analysis

Intermediate-risk pulmonary embolism (PE) has anticoagulation as the standard treatment, while reperfusion strategies remain a matter of debate. In this context, mechanical thrombectomy has...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...